Inogen (NASDAQ:INGN) Lowered to Hold Rating by StockNews.com

StockNews.com cut shares of Inogen (NASDAQ:INGN) from a buy rating to a hold rating in a research note issued to investors on Thursday morning.

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Inogen in a research note on Friday, November 8th.

Inogen Stock Performance

NASDAQ INGN opened at $9.21 on Thursday. The firm’s fifty day moving average is $9.70 and its two-hundred day moving average is $9.59. Inogen has a one year low of $4.93 and a one year high of $13.33. The firm has a market cap of $219.36 million, a PE ratio of -4.09 and a beta of 1.04.

Hedge Funds Weigh In On Inogen

A number of large investors have recently bought and sold shares of INGN. Divisadero Street Capital Management LP raised its holdings in Inogen by 682.3% during the second quarter. Divisadero Street Capital Management LP now owns 2,346,766 shares of the medical technology company’s stock worth $19,079,000 after purchasing an additional 2,046,766 shares in the last quarter. Brown Capital Management LLC lifted its holdings in shares of Inogen by 26.6% in the 1st quarter. Brown Capital Management LLC now owns 1,975,312 shares of the medical technology company’s stock valued at $15,941,000 after buying an additional 414,903 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Inogen by 312.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company’s stock valued at $1,694,000 after buying an additional 132,287 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of Inogen by 29.3% during the 2nd quarter. AQR Capital Management LLC now owns 570,994 shares of the medical technology company’s stock worth $4,642,000 after purchasing an additional 129,307 shares in the last quarter. Finally, Sanctuary Advisors LLC acquired a new position in shares of Inogen during the 2nd quarter worth $651,000. Hedge funds and other institutional investors own 89.94% of the company’s stock.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.